Company Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems.
The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits.
It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies.
The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America.
The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005.
Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2000 |
| IPO Date | Oct 27, 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 575 |
| CEO | Christian O. Henry |
Contact Details
Address: 1305 O’Brien Drive Menlo Park, California 94025 United States | |
| Phone | 650 521 8000 |
| Website | pacb.com |
Stock Details
| Ticker Symbol | PACB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001299130 |
| CUSIP Number | 69404D108 |
| ISIN Number | US69404D1081 |
| Employer ID | 16-1590339 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Christian O. Henry M.B.A. | President, Chief Executive Officer and Director |
| Mark Van Oene Ph.D. | Chief Operating Officer |
| Dr. Stephen Turner Ph.D. | Co-Founder |
| James R. Gibson II | Chief Financial Officer |
| Michele Farmer CPA | Vice President and Chief Accounting Officer |
| Dr. Brett Atkins J.D., Ph.D. | General Counsel and Corporate Secretary |
| David Ruggiero | Global Head of Sales and Service |
| Natalie Welch | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | 8-K | Current Report |
| May 29, 2025 | SD | Form - SD |
| May 20, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |